RNTX · Rein Therapeutics, Inc.
$0.78
-0.01 (-0.98%)
At close · Jul 27
Market Cap
$66.86M
Shares
85.54M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$49.9M
+20.7%
FY2025
Diluted EPS
-$1.96
+44.2%
FY2025
Operating Cash Flow
-$19.36M
+13.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| $11.05M | $11.03M | $14.25M | $3.99M | $17.97M | $17.01M | $11.17M | $17.66M | $18.45M | $14.24M | $10.28M | $7.83M | |
| $10.5M | $10.9M | $13.86M | $11.36M | $9.68M | $9.6M | $9.33M | $12.29M | $13.45M | $8.77M | $7.89M | $5.06M | |
| — | $1000 | $63K | $119K | $169K | $121K | $163K | $155K | $218K | $129K | $232K | $325K | |
| — | — | $0 | $928K | — | — | — | — | — | — | — | — | |
| $50.25M | $50.63M | $65.11M | $16.28M | $27.65M | $26.61M | $20.5M | $29.96M | $31.9M | $23.01M | $18.17M | $12.89M | |
| -$50.25M | -$50.63M | -$65.11M | -$16.28M | -$27.65M | -$26.61M | -$20.5M | -$29.96M | -$31.9M | -$23.01M | -$18.17M | -$12.89M | |
| — | -$50.63M | -$65.05M | -$16.16M | -$27.48M | -$26.48M | -$20.33M | -$29.8M | -$31.68M | -$22.88M | -$17.94M | -$12.57M | |
| -$668K | $48K | $685K | $544K | $318K | $441K | -$661K | $587K | — | — | — | — | |
| — | -$712K | -$1.54M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$50.24M | -$49.9M | -$62.9M | -$15.7M | -$27.33M | -$26.16M | -$27.33M | -$29.37M | -$31.55M | -$22.6M | -$18.12M | -$12.88M | |
| — | — | — | — | — | — | — | -$29.37M | -$31.55M | -$22.65M | -$18.2M | -$12.95M | |
| -$50.24M | -$49.92M | -$62.84M | -$15.75M | -$27.36M | -$26.18M | -$21.17M | -$29.36M | -$31.52M | -$22.64M | -$18.12M | -$12.88M | |
| USD/shares | — | -$1.96 | -$3.51 | -$3.42 | -$6.02 | -$5.89 | — | — | — | — | — | — |
| USD/shares | — | -$1.96 | -$3.51 | -$3.42 | -$6.02 | -$5.89 | — | — | — | — | — | — |
| shares | — | 25.44M | 17.94M | 4.6M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 21.48K | 20.04K |
| shares | — | 25.44M | 17.94M | 4.6M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 21.48K | 20.04K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.22×
EV/EBIT
—
Peer median 26.73×
P/E (TTM)
—
Peer median 2.57×
Peer medians compare against the 290 similar-size Biotechnology companies (of 521 listed).